SIACI of cetuximab, an anti-epidermal growth factor receptor (EGFR) mAb, has been safe and well tolerated in patients with recurrent glioblastoma in a phase I/II trial, with no dose-limiting toxicity (DLT) up to 250 mg/m2 [42]; a phase II trial is ongoing (Table 2). This evidence concerns the gene EGFR and glioblastoma.